Dietary Treatment of Crohn's Disease

Completed · Phase 1/Phase 2 · Has a placebo group

Conditions studied: Crohn's Disease, Inflammatory Bowel Disease

In brief

Our objective is to determine whether a specific dietary intervention or a fructooligosaccharide (FOS) supplement has anti-oxidant or prebiotic effects and whether it is beneficial in the treatment of Crohn's Disease (CD.

Key facts

Study ID

NCT00343642

Run by

Rush University Medical Center

People needed

73

Starts

2006-09-01

Expected to finish

2012-10-01

Last updated by the study team

2021-06-09

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Documented ileocolonic or colonic CD based on classical history and classical endoscopic or surgical findings and histology compatible with CD;
• Induction of remission with medical therapy within 9 months of the study;
• Inactive CD for at least 2 weeks with CDAI score less than 150;
• No change in IBD medication doses for 3 months;
• No change in smoking habits a month prior to enrollment (because smoking may exacerbate CD) and acceptance of not-changing smoking habits during the term of the study).

You may not qualify if…

• Patients with history of bowel obstruction and/or known strictures (as the high fiber content may precipitate obstruction);
• Patients with extensive colonic or ileocolonic resection;
• Patients with ileostomies or colostomies with diverted fecal stream;
• Patients with isolated perianal/anorectal disease;
• Patients with surgically induced remission;
• Concomitant infection (e.g., C. difficile colitis);
• Use of antibiotics within 4 weeks, or steroids, herbal remedies or diet therapies within 2 weeks of the onset of the trial or during the study;
• Use of potential IBD exacerbators such as NSAIDs within 1 wk of the study;
• Acute illness requiring immediate hospitalization for CD or other reasons;
• Presence of symptomatic organic GI disease other than CD, hemorrhoids, hiatal hernia; GERD;
• Pre-existent organ failure or severe comorbidities as these may change Gl flora:
• Liver disease (cirrhosis or persistently abnormal AST or ALT that are 2X> normal);
• Kidney disease (creatinine>2.0 mg/dL);
• Uncontrolled psychiatric illness;
• Clinically important lung disease or heart failure;
• HIV disease;
• Alcoholism;
• Transplant recipients;
• Patients receiving other immunosuppressant medications for comorbidities (e.g. Enbrel for rheumatoid arthritis);
• Presence of short bowel syndrome or severe malnutrition with ideal body weight less than or equal to 90% or predicted;
• Estimated survival <1 year and Karnofsky performance status <50%;
• Desire to become pregnant during study or current pregnancy or nursing;
• Desire to change smoking-status during the study;
• Daily use of anticoagulation and antiplatelet medications;
• Complicated IBD with anticipation of imminent surgical intervention during the term of the study;

Where it is running

• Gastroenterology Associates of Central Georgia — Macon, Georgia, United States
• Rush University Medical Center — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.